Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304

類似資料

• CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer in a prospective trial: CALGB 150304
  著者:: Edelman, Martin J., 等
  出版事項: (2012)
• Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non–Small-Cell Lung Cancer
  著者:: Edelman, Martin J., 等
  出版事項: (2012)
• Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407
  著者:: Govindan, Ramaswamy, 等
  出版事項: (2011)
• Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report
  著者:: Dudek, Arkadiusz Z., 等
  出版事項: (2012)
• Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)
  著者:: Jahan, Thierry, 等
  出版事項: (2011)